Literature DB >> 16328567

Recurrence of Cushing's disease preceded by the reappearance of ACTH and cortisol responses to desmopressin test.

Chiara Dall'Asta1, Laura Barbetta1, Luigi Bonavina1, Paolo Beck-Peccoz2, Bruno Ambrosi3,4.   

Abstract

At present no single test is considered of absolute value in identifying patients successfully operated for Cushing's disease who are at risk for recurrence. The present report describes the first two patients in whom ACTH/cortisol abnormal responses to desmopressin disappeared after cure and then clearly reappeared during long-term follow-up several months before the clinical and hormonal features of hypercortisolism became manifest. The case histories of 2 young women are reported. The diagnosis of Cushing's disease was made on the basis of clinical features and standard hormonal criteria. Both patients, showing abnormal ACTH/cortisol rises after desmopressin test, underwent pituitary adenomectomy by transsphenoidal surgery and after operation plasma ACTH and serum cortisol levels were 0.2 and 0.4 pmol/l and 56 and 32 nmol/l, respectively. During the follow-up both patients underwent desmopressin (10 microg iv), ovine CRH (1 microg/kg iv) and 1 mg dexamethasone tests at 1, 6, 12, 24 months after surgery. In these two cases the ACTH/cortisol response to desmopressin normalized following pituitary adenomectomy, concomitantly with the normalization of all the other clinical and hormonal parameters. Subsequently abnormal rises after the synthetic AVP analogue administration appeared: paradoxical ACTH/cortisol increments after desmopressin occurred 24 and 6 months before any other hormonal or clinical sign of recurrence of hypercortisolism. As desmopressin may be able to stimulate ACTH/cortisol release in Cushing's disease, but not in normal subjects, we suggest that it can have a role in early identifying successfully operated Cushing's patients at risk for recurrence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16328567     DOI: 10.1007/s11102-005-0425-9

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  31 in total

1.  Transsphenoidal surgery for Cushing's disease: defining cure and following outcome.

Authors:  John Newell-Price
Journal:  Clin Endocrinol (Oxf)       Date:  2002-01       Impact factor: 3.478

2.  Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease.

Authors:  Alberto M Pereira; Maarten O van Aken; Hans van Dulken; Pieter J Schutte; Nienke R Biermasz; Jan W A Smit; Ferdinand Roelfsema; Johannes A Romijn
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

Review 3.  Diagnosis and complications of Cushing's syndrome: a consensus statement.

Authors:  G Arnaldi; A Angeli; A B Atkinson; X Bertagna; F Cavagnini; G P Chrousos; G A Fava; J W Findling; R C Gaillard; A B Grossman; B Kola; A Lacroix; T Mancini; F Mantero; J Newell-Price; L K Nieman; N Sonino; M L Vance; A Giustina; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

4.  Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity.

Authors:  S Tsagarakis; V Vasiliou; P Kokkoris; G Stavropoulos; N Thalassinos
Journal:  Clin Endocrinol (Oxf)       Date:  1999-10       Impact factor: 3.478

5.  Restoration of dexamethasone suppression by incomplete adenomectomy in Cushing's disease.

Authors:  W J Jeffcoate; S Dauncey; C Selby
Journal:  Clin Endocrinol (Oxf)       Date:  1985-08       Impact factor: 3.478

6.  A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome.

Authors:  J Newell-Price; L Perry; S Medbak; J Monson; M Savage; M Besser; A Grossman
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

7.  The desmopressin test in the differential diagnosis between Cushing's disease and pseudo-Cushing states.

Authors:  M Moro; P Putignano; M Losa; C Invitti; C Maraschini; F Cavagnini
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

8.  Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women.

Authors:  G Ceresini; M Freddi; P Paccotti; G Valenti; I Merchenthaler
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

9.  The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion.

Authors:  S Tsagarakis; C Tsigos; V Vasiliou; P Tsiotra; J Kaskarelis; C Sotiropoulou; S A Raptis; N Thalassinos
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

10.  Assessment of endocrine function after transsphenoidal surgery for Cushing's disease.

Authors:  D R McCance; D S Gordon; T F Fannin; D R Hadden; L Kennedy; B Sheridan; A B Atkinson
Journal:  Clin Endocrinol (Oxf)       Date:  1993-01       Impact factor: 3.478

View more
  3 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

2.  Usefulness of desmopressin testing to predict relapse during long-term follow-up in patients in remission from Cushing's disease.

Authors:  Alberto Giacinto Ambrogio; Massimiliano Andrioli; Martina De Martin; Francesco Cavagnini; Francesca Pecori Giraldi
Journal:  Endocr Connect       Date:  2017-10-10       Impact factor: 3.335

3.  Indication to dynamic and invasive testing in Cushing's disease according to different neuroradiological findings.

Authors:  E Ferrante; M Barbot; A L Serban; F Ceccato; G Carosi; L Lizzul; E Sala; A Daniele; R Indirli; M Cuman; M Locatelli; R Manara; M Arosio; M Boscaro; G Mantovani; C Scaroni
Journal:  J Endocrinol Invest       Date:  2021-10-26       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.